Cagrilintide Phase 3 Trial Registered, Not Yet Recruiting

A new clinical trial listing for cagrilintide appeared on ClinicalTrials.gov, dated August 4, 2026. The study, registered as NCT07745504, is titled "A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight." The trial is listed as Phase 3. Its current status is not yet recruiting. According to the listing, the study is designed to compare two different injectable versions of cagrilintide against placebo in participants with excess body weight. No enrollment has begun according to the current status. Cagrilintide remains an unapproved compound under research investigation. This listing reflects only the trial's registration details as posted, including its phase and status. No outcome data, efficacy findings, or safety results are included in this update, since the trial has not started recruiting participants. Further details on study design, eligibility, and timelines may be available through the official trial registration page. Readers seeking background on cagrilintide can consult the compound overview for additional context.